Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G pTau 217 Plasma Assay
· Financial Post
GHENT, Belgium & TOKYO -- H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human plasma (K2EDTA). Read More
Visit playerbros.org for more information.